Participated · Series B · Aug 2026

ClearJet operates a carrier-agnostic "SuperCarrier" delivery network that combines staffing, sorting, and ground infrastructure to place consolidated e-commerce packages on commercial flights already scheduled between U.S. cities. Its AI models route parcels across a network of 95 U.S. airports to optimize for cost, speed, and geography. The company currently moves more than 30 million packages a year and reports both delivery volumes and revenue growing 2.5x annually. ClearJet says its configurable Air Zone Skip model can reduce shipping costs by up to 35% while delivering packages 1–3 days faster. Customers include multi-billion dollar retail brands, e-commerce platforms, 3PLs, marketplaces, and regional carriers such as OnTrac and Veho. ClearJet is headquartered in Austin, Texas and describes its platform as profitable.

Led · Seed · Jul 2026

INTALUS develops processes to integrate ceramics into metals, addressing gaps that conventional coatings leave. The company’s metal-ceramic infusion approach is described as relevant across the national security sector and additional markets. Coverage notes INTALUS is scaling rapidly following the announced financing. The team and investor partnership, including Gene Skiba, Origin Ventures and Scout Ventures, are highlighted as supporters of the company’s growth. The articles do not provide revenue, user metrics, founding year, or location information.

Led · Seed · May 2026

Century Health develops the Century Health Abstraction & Retrieval Model (CHARM), an AI-powered platform that automates identification, curation, and enrichment of fragmented clinical data into research-ready real-world evidence. CHARM has achieved 97% accuracy when validated against clinical expert judgment. Over the past year the company grew its specialty provider data network 60x, spanning neurology, nephrology, ophthalmology, respiratory, metabolic, and immunology, and counts multiple Top 5 pharma companies as partners. Century Health is continuing to expand its disease-specific registry network, deepen pharma collaborations, and advance CHARM for complex abstraction and data harmonization. The company raised a $5M seed round to scale collaborations, grow its provider network, and expand its AI-powered data curation infrastructure.

Participated · Series A · Dec 2025

Headquartered in San Francisco and led by CEO Jay Dawani, Lemurian Labs has built a platform that combines compiler technology with runtime orchestration to let developers write AI code once and deploy it on any hardware. Its hardware-agnostic approach promises faster deployment cycles, greater flexibility and lower infrastructure costs at scale. The company is positioning the platform for organizations seeking sustainable compute and open AI innovation. Fresh capital will be directed toward expanding the engineering team, accelerating product development and deepening partnerships across the AI ecosystem. Although specific revenue or user figures were not disclosed, the company previously completed a seed round in 2022. Lemurian Labs believes its technology can reduce the friction of moving AI workloads between edge devices, cloud instances and on-prem servers, potentially widening its addressable market.

Participated · Series A · Oct 2025

Medmo operates an end-to-end orchestration platform that allows ordering providers to manage referrals for diagnostic imaging exams such as MRIs, CTs, mammograms, ultrasounds, and X-rays. The New York-based company’s technology automates the entire patient journey—from initial engagement and scheduling through prior authorization and delivery of results—helping provider groups streamline radiology workflows. Medmo’s solution is live in all 50 states and has facilitated more than one million patient journeys to date. Its AI-powered care-coordination capabilities have made it a preferred platform for providers seeking to improve efficiency and patient experience. With its expanding footprint, the company plans to build additional offerings tailored for insurance carriers. The recently secured capital will fund these developmental efforts while supporting broader operational growth.